The Prognostic Significance Of Circulating Tumor DNA For Patients With Pancreatic Adenocarcinoma

OBJECTIVES: This prospective study aimed to investigate the role of KRAS mutation subtype in the prediction of the prognosis of resectable pancreatic cancer.METHODS: The KRAS mutation status was tested after.We used the Kaplan– Meier method,l,and Cox' s model to evaluate the impact of KRAS status on the overall survival(OS),adjusting for age,stage of disease,clinical performance status,CA19-9 levels,and surgical procedures.RESULTS: A total of 25 patients(men: 16;mean age: 67± 9.4 years)were included: 7 harbored a KRAS mutation.There was no difference in the average and sex between patients with a G12 D mutant KRAS.However,the patients with a Kras mutation had a significantly shorter OS(6 months;95% CI: 6.4– 9.7)compared with the other patients(OS: 9 months;95% CI: 10– 13;HR: 1.47;P= 0.003).Multivariate analyses identified KRAS as an independent predictor for worse prognosis(HR: 1.44;P= 0.01).CONCLUSIONS: The KRAS mutation subtype is an independent prognostic marker for resectable pancreatic ductal carcinoma and should be considered when evaluating the prognosis of patients with resectable pancreatic cancer after surgery.